Unibest 优贝德
← Back to patent-cliff list

奥拉帕利

Tier A — Act now

Olaparib · all drugs expiring in 2028 →

阿斯利康
Originator
2014
First approval
2028
Expiry (public)
$4.73B ▲
Peak sales
化学药
Type

Targets：PARP-2、PARP-3、PARP1

Brand：Lynparza、利普卓

Indications (approved)：子宫内膜癌、去势抵抗性前列腺肿瘤、前列腺癌、腹膜癌、卵巢上皮癌、输卵管癌、胰腺癌、卵巢癌

Regional status

US
批准上市
2014-12-19
EU
批准上市
2014-12-16
China
批准上市
2018-08-22
Japan
批准上市
2018-01-19

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 6 · Total yield 1.27 kg
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
OLAP-00116859-59-9Available3-hydroxyisobenzofuran-1(3H)-one
OLAP-002868-85-9Availabledimethyl phosphonate
OLAP-00361260-15-9Availabledimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate
OLAP-004218301-22-5Available2-fluoro-5-formylbenzonitrile
OLAP-005763114-25-6Available(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile
OLAP-006763114-26-7Available2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid
OLAP-00757260-71-6Availabletert-butyl piperazine-1-carboxylate
OLAP-008763114-04-1Availabletert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate
OLAP-009763111-47-3Available4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one
OLAP-0104023-34-1Availablecyclopropanecarbonyl chloride
OptimisedRoute 2Steps 6 · Total yield 8.67 g
Synthetic routes & intermediates Route 2
CodeCAS No.Intermediate
OLAP-00116859-59-9Available3-hydroxyisobenzofuran-1(3H)-one
OLAP-004218301-22-5Available2-fluoro-5-formylbenzonitrile
OLAP-005763114-25-6Available(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile
OLAP-006763114-26-7Available2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid
OLAP-0104023-34-1Availablecyclopropanecarbonyl chloride
OLAP-0111021298-68-9Available2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzonitrile
OLAP-0121021298-67-8Availablecyclopropyl(piperazin-1-yl)methanone hydrochloride
OLAP-013110-85-0Availablepiperazine

Frequently asked questions

What are the approved indications of Olaparib?

Approved indications include: 子宫内膜癌, 去势抵抗性前列腺肿瘤, 前列腺癌, 腹膜癌, 卵巢上皮癌, 输卵管癌, 胰腺癌, 卵巢癌.

When does the Olaparib patent expire?

Based on public sources, the Olaparib patent expires in 2028.

How many synthesis routes are recorded for Olaparib?

2 synthesis routes are recorded; the shortest is 6 steps with 1.27 kg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Olaparib intermediates?

13 intermediate CAS of Olaparib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Olaparib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24